This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Mucosa-associated lymphatic tissue (MALT) lymphoma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Gastric mucosa-associated tissue lymphoma (MALT lymphoma) is a rare mature B-cell neoplasm associated with H. pylori infection that is curable by antibiotics therapy alone.

The pathological diagnosis of gastric MALT lymphoma can be reached by histological examination, immunohistochemical staining and B-cell clonality analysis.

Management of MALT lymphoma

First-line treatment

Gastric MALT lymphoma: localised disease

  • 1 or more lines of Helicobacter pylori eradication therapy should be offered, without any concurrent therapy, to people with H. pylori-positive gastric MALT lymphoma
  • H. pylori eradication therapy should be considered for people with H. pylori-negative gastric MALT lymphoma
  • consider 'watch and wait' (observation without therapy) for people with gastric MALT lymphoma that responds clinically and endoscopically to H. pylori eradication therapy but who have residual disease shown by surveillance biopsies of the stomach, unless high-risk features are present

  • for people with residual MALT lymphoma after H. pylori eradication therapy who are at high risk of progression [H. pylori-negative at initial presentation or t(11:18) translocation], options include:
    • chemotherapy (for example, chlorambucil or CVP) in combination with rituximab or
    • gastric radiotherapy

  • for people with progressive gastric MALT lymphoma, options include:
    • chemotherapy (for example, chlorambucil or CVP) in combination with rituximab or
    • gastric radiotherapy

Non-gastric MALT lymphoma

  • chemotherapy (for example, chlorambucil or CVP) in combination with rituximab should be offered to people with non-gastric MALT lymphoma for whom radiotherapy is not suitable or who have disseminated disease and need treatment
  • radiotherapy should be considered for people with localised disease sites of non-gastric MALT lymphoma, irrespective of stage
  • consider 'watch and wait' (observation without therapy) for people with clinically non-progressive localised non-gastric MALT lymphoma that is unlikely to result in vital organ dysfunction, who are asymptomatic and for whom radiotherapy is not suitable.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.